Saltoro Capital’s VYNE Therapeutics VYNE Stock Holding History

Saltoro Capital’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-5,021	Closed	-$571K	–	154
2020 Q4	$571K	Buy	+5,021	New	+$631K	0.28%	70

Other funds holding VYNE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

HVC

Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

Saltoro Capital's VYNE Position: Q1 2021 in Review

Saltoro Capital sold out of VYNE Therapeutics (VYNE) in Q1 2021, closing a stake of 5,021 shares — an estimated $571K sold.

Saltoro Capital first reported a position in VYNE in Q4 2020 and held it in 1 quarter. The position peaked at $571K in Q4 2020. 89 funds tracked by Wall St. Rank hold VYNE as of Q1 2021.

Saltoro Capital reported no remaining VYNE Therapeutics position as of Q1 2021 after selling out during the quarter.
Saltoro Capital sold 5,021 VYNE Therapeutics shares in Q1 2021, an estimated $571K.
Saltoro Capital first reported a position in VYNE Therapeutics in Q4 2020 and held it in 1 quarter.
Saltoro Capital's VYNE Therapeutics position peaked at $571K in Q4 2020.
89 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2021.

Based on Saltoro Capital's 13F filing for Q1 2021, filed 14 May 2021.